Equity Joint Venture (Details) |
3 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 30, 2017
USD ($)
|
Sep. 30, 2017
USD ($)
|
Jul. 01, 2017
USD ($)
|
Apr. 01, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Sep. 24, 2016
USD ($)
|
Jun. 25, 2016
USD ($)
|
Mar. 26, 2016
USD ($)
|
Dec. 30, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Dec. 26, 2015
USD ($)
|
Feb. 29, 2016
USD ($)
legal_entity
|
|||||
| Schedule of Equity Method Investments [Line Items] | ||||||||||||||||
| Estimated license fees earned over time | $ 293,000,000 | |||||||||||||||
| Operating income related to licensed IP | $ 0 | $ 0 | $ 25,000,000 | $ 27,000,000 | $ 31,000,000 | $ 24,000,000 | $ 26,000,000 | $ 7,000,000 | $ 52,000,000 | $ 88,000,000 | $ 0 | |||||
| Equity method investment | [1],[2] | 58,000,000 | 59,000,000 | 58,000,000 | 59,000,000 | |||||||||||
| THATIC JV | ||||||||||||||||
| Schedule of Equity Method Investments [Line Items] | ||||||||||||||||
| Number of legal entities | legal_entity | 2 | |||||||||||||||
| Equity method investment | 0 | 0 | ||||||||||||||
| Prepayment and other receivables - related parties | $ 3,000,000 | $ 0 | 3,000,000 | 0 | ||||||||||||
| Development fee | THATIC JV | ||||||||||||||||
| Schedule of Equity Method Investments [Line Items] | ||||||||||||||||
| Recognized credits to research and development expenses | 36,000,000 | 0 | ||||||||||||||
| Other services fees | THATIC JV | ||||||||||||||||
| Schedule of Equity Method Investments [Line Items] | ||||||||||||||||
| Recognized credits to research and development expenses | 12,000,000 | |||||||||||||||
| Royalty income | THATIC JV | ||||||||||||||||
| Schedule of Equity Method Investments [Line Items] | ||||||||||||||||
| Operating income related to licensed IP | $ 0 | $ 0 | ||||||||||||||
| ||||||||||||||||
| X | ||||||||||
- Definition Total amount before taxes of estimated other operating income from license fees expected be earned over several years pursuant to a licensing agreement. No definition available.
|
| X | ||||||||||
- Definition Number of Legal Entities No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|